NCT05038410View on ClinicalTrials.gov

Study to Investigate the Mechanism of Action of an Oral Enzyme Treatment With Bromelain, Trypsin and Rutoside Versus Placebo in Subjects With OsTeoarthritis

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

October 5, 2022

Study Completion Date

October 5, 2022

Conditions
Osteoarthritis
Interventions
DRUG

Wobenzym®

Wobenzym®

OTHER

Placebo

Microcrystalline cellulose

Trial Locations (5)

1020

Centre Hospitalier Universitaire (CHU) Brugmann, Brussels

1090

UZ Brussel, Jette

1200

Cliniques Universitaires Saint Luc UCL, Brussels

2020

Ziekenhuis Netwerk Antwerpen (ZNA) Middelheim, Antwerp

4000

Centre Hospitalier Régional de la Citadelle, Liège

Sponsors

Collaborators (1)

Artialis
All Listed Sponsors
collaborator

Société des Produits Nestlé (SPN)

INDUSTRY

collaborator

Artialis

INDUSTRY

lead

Mucos Pharma GmbH & Co. KG

INDUSTRY

NCT05038410 - Study to Investigate the Mechanism of Action of an Oral Enzyme Treatment With Bromelain, Trypsin and Rutoside Versus Placebo in Subjects With OsTeoarthritis | Biotech Hunter | Biotech Hunter